biomarker

First-line treatment guidelines: combination strategy

NIVOREN GETUG-AFU 26: Updates and implications

The value of PD-L1 as a biomarker beyond lung cancers

OpACIn-neo trial RFS and biomarker analyses: optimal neoadjuvant ipi/nivo dosing in melanoma

Biomarker-directed BISCAY data: durvalumab plus targeted therapies in mUC

Vinorelbine in Mesothelioma: the upcoming VIM trial

The omega score: an emerging biomarker for risk determination

KEYNOTE-048: pembrolizumab monotherapy for frontline R/M HNSCC

Molecular aging and p16INK4a in testicular cancer survivors

How can pharmacists approach the ‘grey area’ surrounding PD-L1 testing?

Assessment and diagnostic workup for NSCLC in 2018

Economic impact of NGS for NSCLC diagnostics

Using immunotherapy wisely for prostate cancer

Olaparib plus abiraterone for mCRPC: are biomarkers necessary?

ABACUS trial: preoperative atezolizumab in urothelial carcinoma

EMA restrict pembrolizumab/atezolizumab usage in urothelial cancer